APO Research
Talk to an analyst

APO RESEARCH · REPORT

Histone Deacetylase (HDAC) Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Histone Deacetylase (HDAC) Inhibitors Market Outlook and Growth Opportunities 2026

26 December 2025191 pages

Choose your research edition.

Industry ResearchHistone Deacetylase (HDAC) Inhibitors Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Histone Deacetylase (HDAC) Inhibitors Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Histone Deacetylase (HDAC) Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Histone Deacetylase (HDAC) Inhibitors Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Histone Deacetylase (HDAC) Inhibitors Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Histone Deacetylase (HDAC) Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Histone Deacetylase (HDAC) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Histone Deacetylase (HDAC) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Histone Deacetylase (HDAC) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Histone Deacetylase (HDAC) Inhibitors market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Histone Deacetylase (HDAC) Inhibitors market include 4SC, Novartis, TetraLogic, Repligen, Onxeo, Mirati Therapeutics, MEI Pharma, Curis and CrystalGenomics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Histone Deacetylase (HDAC) Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Histone Deacetylase (HDAC) Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Histone Deacetylase (HDAC) Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Histone Deacetylase (HDAC) Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Histone Deacetylase (HDAC) Inhibitors Segment by Company

4SC

Novartis

TetraLogic

Repligen

Onxeo

Mirati Therapeutics

MEI Pharma

Curis

CrystalGenomics

Chroma Therapeutics

Chipscreen Biosciences

Celleron Therapeutics

Acetylon Pharmaceuticals

Histone Deacetylase (HDAC) Inhibitors Segment by Type

Benzamide

Cyclic Peptide

Hydroxamate

Fatty Acid

Histone Deacetylase (HDAC) Inhibitors Segment by Application

Treatment of Malignant Tumors

Chronic Disease Treatment

Others

Histone Deacetylase (HDAC) Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Histone Deacetylase (HDAC) Inhibitors status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Histone Deacetylase (HDAC) Inhibitors market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Histone Deacetylase (HDAC) Inhibitors significant trends, drivers, influence factors in global and regions.

6. To analyze Histone Deacetylase (HDAC) Inhibitors competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Histone Deacetylase (HDAC) Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Histone Deacetylase (HDAC) Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Histone Deacetylase (HDAC) Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Histone Deacetylase (HDAC) Inhibitors market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Histone Deacetylase (HDAC) Inhibitors industry.

Chapter 3: Detailed analysis of Histone Deacetylase (HDAC) Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Histone Deacetylase (HDAC) Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Histone Deacetylase (HDAC) Inhibitors in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Histone Deacetylase (HDAC) Inhibitors Industry Trends Table 2. Histone Deacetylase (HDAC) Inhibitors Industry Drivers Table 3. Histone Deacetylase (HDAC) Inhibitors Industry Opportunities and Challenges Table 4. Histone Deacetylase (HDAC) Inhibitors Industry Restraints Table 5. Global Histone Deacetylase (HDAC) Inhibitors Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Histone Deacetylase (HDAC) Inhibitors Revenue Share by Company (2021-2026) Table 7. Global Histone Deacetylase (HDAC) Inhibitors Sales Volume by Company (Tons) & (2021-2026) Table 8. Global Histone Deacetylase (HDAC) Inhibitors Sales Volume Share by Company (2021-2026) Table 9. Global Histone Deacetylase (HDAC) Inhibitors Average Price (US$/Ton) of Company (2021-2026) Table 10. Global Histone Deacetylase (HDAC) Inhibitors Company Ranking, (2024-2026) & (USD Million) Table 11. Global Histone Deacetylase (HDAC) Inhibitors Key Company Manufacturing Base & Headquarters Table 12. Global Histone Deacetylase (HDAC) Inhibitors Company, Product Type & Application Table 13. Global Histone Deacetylase (HDAC) Inhibitors Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Histone Deacetylase (HDAC) Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Benzamide Table 18. Significant Companies of Cyclic Peptide Table 19. Significant Companies of Hydroxamate Table 20. Significant Companies of Fatty Acid Table 21. Global Histone Deacetylase (HDAC) Inhibitors Sales Volume by Type 2021 VS 2025 VS 2032 (Tons) Table 22. Global Histone Deacetylase (HDAC) Inhibitors Sales Volume by Type (2021-2026) & (Tons) Table 23. Global Histone Deacetylase (HDAC) Inhibitors Sales Volume by Type (2027-2032) & (Tons) Table 24. Global Histone Deacetylase (HDAC) Inhibitors Sales Volume Share by Type (2021-2026) Table 25. Global Histone Deacetylase (HDAC) Inhibitors Sales Volume Share by Type (2027-2032) Table 26. Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type (2021-2026) Table 30. Global Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Treatment of Malignant Tumors Table 32. Significant Companies of Chronic Disease Treatment Table 33. Significant Companies of Others Table 34. Global Histone Deacetylase (HDAC) Inhibitors Sales Volume by Application 2021 VS 2025 VS 2032 (Tons) Table 35. Global Histone Deacetylase (HDAC) Inhibitors Sales Volume by Application (2021-2026) & (Tons) Table 36. Global Histone Deacetylase (HDAC) Inhibitors Sales Volume by Application (2027-2032) & (Tons) Table 37. Global Histone Deacetylase (HDAC) Inhibitors Sales Volume Share by Application (2021-2026) Table 38. Global Histone Deacetylase (HDAC) Inhibitors Sales Volume Share by Application (2027-2032) Table 39. Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application (2021-2026) Table 43. Global Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application (2027-2032) Table 44. Global Histone Deacetylase (HDAC) Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 45. Global Histone Deacetylase (HDAC) Inhibitors Sales by Region (2021-2026) & (Tons) Table 46. Global Histone Deacetylase (HDAC) Inhibitors Sales Market Share by Region (2021-2026) Table 47. Global Histone Deacetylase (HDAC) Inhibitors Sales by Region (2027-2032) & (Tons) Table 48. Global Histone Deacetylase (HDAC) Inhibitors Sales Market Share by Region (2027-2032) Table 49. Global Histone Deacetylase (HDAC) Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Region (2021-2026) Table 52. Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Region (2027-2032) Table 54. Global Histone Deacetylase (HDAC) Inhibitors Market Average Price (US$/Ton) by Region (2021-2026) Table 55. Global Histone Deacetylase (HDAC) Inhibitors Market Average Price (US$/Ton) by Region (2027-2032) Table 56. Global Histone Deacetylase (HDAC) Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (Tons) Table 57. Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Histone Deacetylase (HDAC) Inhibitors Sales by Country (2021-2026) & (Tons) Table 59. Global Histone Deacetylase (HDAC) Inhibitors Sales Market Share by Country (2021-2026) Table 60. Global Histone Deacetylase (HDAC) Inhibitors Sales by Country (2027-2032) & (Tons) Table 61. Global Histone Deacetylase (HDAC) Inhibitors Sales Market Share by Country (2027-2032) Table 62. Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Histone Deacetylase (HDAC) Inhibitors Sales Value Market Share by Country (2021-2026) Table 64. Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Histone Deacetylase (HDAC) Inhibitors Sales Value Market Share by Country (2027-2032) Table 66. 4SC Company Information Table 67. 4SC Business Overview Table 68. 4SC Histone Deacetylase (HDAC) Inhibitors Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 69. 4SC Histone Deacetylase (HDAC) Inhibitors Product Portfolio Table 70. 4SC Recent Development Table 71. Novartis Company Information Table 72. Novartis Business Overview Table 73. Novartis Histone Deacetylase (HDAC) Inhibitors Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 74. Novartis Histone Deacetylase (HDAC) Inhibitors Product Portfolio Table 75. Novartis Recent Development Table 76. TetraLogic Company Information Table 77. TetraLogic Business Overview Table 78. TetraLogic Histone Deacetylase (HDAC) Inhibitors Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 79. TetraLogic Histone Deacetylase (HDAC) Inhibitors Product Portfolio Table 80. TetraLogic Recent Development Table 81. Repligen Company Information Table 82. Repligen Business Overview Table 83. Repligen Histone Deacetylase (HDAC) Inhibitors Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 84. Repligen Histone Deacetylase (HDAC) Inhibitors Product Portfolio Table 85. Repligen Recent Development Table 86. Onxeo Company Information Table 87. Onxeo Business Overview Table 88. Onxeo Histone Deacetylase (HDAC) Inhibitors Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 89. Onxeo Histone Deacetylase (HDAC) Inhibitors Product Portfolio Table 90. Onxeo Recent Development Table 91. Mirati Therapeutics Company Information Table 92. Mirati Therapeutics Business Overview Table 93. Mirati Therapeutics Histone Deacetylase (HDAC) Inhibitors Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 94. Mirati Therapeutics Histone Deacetylase (HDAC) Inhibitors Product Portfolio Table 95. Mirati Therapeutics Recent Development Table 96. MEI Pharma Company Information Table 97. MEI Pharma Business Overview Table 98. MEI Pharma Histone Deacetylase (HDAC) Inhibitors Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 99. MEI Pharma Histone Deacetylase (HDAC) Inhibitors Product Portfolio Table 100. MEI Pharma Recent Development Table 101. Curis Company Information Table 102. Curis Business Overview Table 103. Curis Histone Deacetylase (HDAC) Inhibitors Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 104. Curis Histone Deacetylase (HDAC) Inhibitors Product Portfolio Table 105. Curis Recent Development Table 106. CrystalGenomics Company Information Table 107. CrystalGenomics Business Overview Table 108. CrystalGenomics Histone Deacetylase (HDAC) Inhibitors Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 109. CrystalGenomics Histone Deacetylase (HDAC) Inhibitors Product Portfolio Table 110. CrystalGenomics Recent Development Table 111. Chroma Therapeutics Company Information Table 112. Chroma Therapeutics Business Overview Table 113. Chroma Therapeutics Histone Deacetylase (HDAC) Inhibitors Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 114. Chroma Therapeutics Histone Deacetylase (HDAC) Inhibitors Product Portfolio Table 115. Chroma Therapeutics Recent Development Table 116. Chipscreen Biosciences Company Information Table 117. Chipscreen Biosciences Business Overview Table 118. Chipscreen Biosciences Histone Deacetylase (HDAC) Inhibitors Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 119. Chipscreen Biosciences Histone Deacetylase (HDAC) Inhibitors Product Portfolio Table 120. Chipscreen Biosciences Recent Development Table 121. Celleron Therapeutics Company Information Table 122. Celleron Therapeutics Business Overview Table 123. Celleron Therapeutics Histone Deacetylase (HDAC) Inhibitors Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 124. Celleron Therapeutics Histone Deacetylase (HDAC) Inhibitors Product Portfolio Table 125. Celleron Therapeutics Recent Development Table 126. Acetylon Pharmaceuticals Company Information Table 127. Acetylon Pharmaceuticals Business Overview Table 128. Acetylon Pharmaceuticals Histone Deacetylase (HDAC) Inhibitors Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 129. Acetylon Pharmaceuticals Histone Deacetylase (HDAC) Inhibitors Product Portfolio Table 130. Acetylon Pharmaceuticals Recent Development Table 131. Key Raw Materials Table 132. Raw Materials Key Suppliers Table 133. Histone Deacetylase (HDAC) Inhibitors Distributors List Table 134. Histone Deacetylase (HDAC) Inhibitors Customers List Table 135. Research Programs/Design for This Report Table 136. Authors List of This Report Table 137. Secondary Sources Table 138. Primary Sources List of Figures Figure 1. Histone Deacetylase (HDAC) Inhibitors Product Image Figure 2. Global Histone Deacetylase (HDAC) Inhibitors Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Histone Deacetylase (HDAC) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 4. Global Histone Deacetylase (HDAC) Inhibitors Sales (2021-2032) & (Tons) Figure 5. Global Histone Deacetylase (HDAC) Inhibitors Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global Histone Deacetylase (HDAC) Inhibitors Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Benzamide Image Figure 10. Cyclic Peptide Image Figure 11. Hydroxamate Image Figure 12. Fatty Acid Image Figure 13. Global Histone Deacetylase (HDAC) Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032) & (Tons) Figure 14. Global Histone Deacetylase (HDAC) Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Histone Deacetylase (HDAC) Inhibitors Sales Volume Share by Type (2021-2032) Figure 16. Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Histone Deacetylase (HDAC) Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type (2021-2032) Figure 19. Treatment of Malignant Tumors Image Figure 20. Chronic Disease Treatment Image Figure 21. Others Image Figure 22. Global Histone Deacetylase (HDAC) Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032) & (Tons) Figure 23. Global Histone Deacetylase (HDAC) Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Histone Deacetylase (HDAC) Inhibitors Sales Volume Share by Application (2021-2032) Figure 25. Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Histone Deacetylase (HDAC) Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application (2021-2032) Figure 28. Global Histone Deacetylase (HDAC) Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 29. Global Histone Deacetylase (HDAC) Inhibitors Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Histone Deacetylase (HDAC) Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Histone Deacetylase (HDAC) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 33. North America Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Histone Deacetylase (HDAC) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Histone Deacetylase (HDAC) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Histone Deacetylase (HDAC) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 39. South America Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Histone Deacetylase (HDAC) Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Histone Deacetylase (HDAC) Inhibitors Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Histone Deacetylase (HDAC) Inhibitors Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Benzamide
  • Cyclic Peptide
  • Hydroxamate
  • Fatty Acid
Applications
  • Treatment of Malignant Tumors
  • Chronic Disease Treatment
  • Others
Companies covered
  • 4SC
  • Novartis
  • TetraLogic
  • Repligen
  • Onxeo
  • Mirati Therapeutics
  • MEI Pharma
  • Curis
  • CrystalGenomics
  • Chroma Therapeutics
  • Chipscreen Biosciences
  • Celleron Therapeutics
  • Acetylon Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Histone Deacetylase (HDAC) Inhibitors Sales Value (2021-2032)
  4. 1.2.2 Global Histone Deacetylase (HDAC) Inhibitors Sales Volume (2021-2032)
  5. 1.2.3 Global Histone Deacetylase (HDAC) Inhibitors Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Histone Deacetylase (HDAC) Inhibitors Market Dynamics
  1. 2.1 Histone Deacetylase (HDAC) Inhibitors Industry Trends
  2. 2.2 Histone Deacetylase (HDAC) Inhibitors Industry Drivers
  3. 2.3 Histone Deacetylase (HDAC) Inhibitors Industry Opportunities and Challenges
  4. 2.4 Histone Deacetylase (HDAC) Inhibitors Industry Restraints
3 Histone Deacetylase (HDAC) Inhibitors Market by Company
  1. 3.1 Global Histone Deacetylase (HDAC) Inhibitors Company Revenue Ranking in 2025
  2. 3.2 Global Histone Deacetylase (HDAC) Inhibitors Revenue by Company (2021-2026)
  3. 3.3 Global Histone Deacetylase (HDAC) Inhibitors Sales Volume by Company (2021-2026)
  4. 3.4 Global Histone Deacetylase (HDAC) Inhibitors Average Price by Company (2021-2026)
  5. 3.5 Global Histone Deacetylase (HDAC) Inhibitors Company Ranking (2024-2026)
  6. 3.6 Global Histone Deacetylase (HDAC) Inhibitors Company Manufacturing Base and Headquarters
  7. 3.7 Global Histone Deacetylase (HDAC) Inhibitors Company Product Type and Application
  8. 3.8 Global Histone Deacetylase (HDAC) Inhibitors Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Histone Deacetylase (HDAC) Inhibitors Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Histone Deacetylase (HDAC) Inhibitors Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Histone Deacetylase (HDAC) Inhibitors Market by Type
  1. 4.1 Histone Deacetylase (HDAC) Inhibitors Type Introduction
  2. 4.1.1 Benzamide
  3. 4.1.2 Cyclic Peptide
  4. 4.1.3 Hydroxamate
  5. 4.1.4 Fatty Acid
  6. 4.2 Global Histone Deacetylase (HDAC) Inhibitors Sales Volume by Type
  7. 4.2.1 Global Histone Deacetylase (HDAC) Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Histone Deacetylase (HDAC) Inhibitors Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Histone Deacetylase (HDAC) Inhibitors Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Type
  11. 4.3.1 Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Type (2021-2032)
  13. 4.3.3 Global Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type (2021-2032)
5 Histone Deacetylase (HDAC) Inhibitors Market by Application
  1. 5.1 Histone Deacetylase (HDAC) Inhibitors Application Introduction
  2. 5.1.1 Treatment of Malignant Tumors
  3. 5.1.2 Chronic Disease Treatment
  4. 5.1.3 Others
  5. 5.2 Global Histone Deacetylase (HDAC) Inhibitors Sales Volume by Application
  6. 5.2.1 Global Histone Deacetylase (HDAC) Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Histone Deacetylase (HDAC) Inhibitors Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Histone Deacetylase (HDAC) Inhibitors Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Application
  10. 5.3.1 Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Application (2021-2032)
  12. 5.3.3 Global Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application (2021-2032)
6 Histone Deacetylase (HDAC) Inhibitors Regional Sales and Value Analysis
  1. 6.1 Global Histone Deacetylase (HDAC) Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Histone Deacetylase (HDAC) Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Histone Deacetylase (HDAC) Inhibitors Sales by Region: 2021-2026
  4. 6.2.2 Global Histone Deacetylase (HDAC) Inhibitors Sales by Region (2027-2032)
  5. 6.3 Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Region (2021-2032)
  7. 6.4.1 Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Region: 2021-2026
  8. 6.4.2 Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Region (2027-2032)
  9. 6.5 Global Histone Deacetylase (HDAC) Inhibitors Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Histone Deacetylase (HDAC) Inhibitors Sales Value (2021-2032)
  12. 6.6.2 North America Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Histone Deacetylase (HDAC) Inhibitors Sales Value (2021-2032)
  15. 6.7.2 Europe Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Histone Deacetylase (HDAC) Inhibitors Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Histone Deacetylase (HDAC) Inhibitors Sales Value (2021-2032)
  21. 6.9.2 South America Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Histone Deacetylase (HDAC) Inhibitors Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Country, 2025 VS 2032
7 Histone Deacetylase (HDAC) Inhibitors Country-level Sales and Value Analysis
  1. 7.1 Global Histone Deacetylase (HDAC) Inhibitors Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Histone Deacetylase (HDAC) Inhibitors Sales by Country (2021-2032)
  4. 7.3.1 Global Histone Deacetylase (HDAC) Inhibitors Sales by Country (2021-2026)
  5. 7.3.2 Global Histone Deacetylase (HDAC) Inhibitors Sales by Country (2027-2032)
  6. 7.4 Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Country (2021-2032)
  7. 7.4.1 Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Country (2021-2026)
  8. 7.4.2 Global Histone Deacetylase (HDAC) Inhibitors Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Histone Deacetylase (HDAC) Inhibitors Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Histone Deacetylase (HDAC) Inhibitors Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 4SC
  2. 8.1.1 4SC Company Information
  3. 8.1.2 4SC Business Overview
  4. 8.1.3 4SC Histone Deacetylase (HDAC) Inhibitors Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 4SC Histone Deacetylase (HDAC) Inhibitors Product Portfolio
  6. 8.1.5 4SC Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Histone Deacetylase (HDAC) Inhibitors Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Histone Deacetylase (HDAC) Inhibitors Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 TetraLogic
  14. 8.3.1 TetraLogic Company Information
  15. 8.3.2 TetraLogic Business Overview
  16. 8.3.3 TetraLogic Histone Deacetylase (HDAC) Inhibitors Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 TetraLogic Histone Deacetylase (HDAC) Inhibitors Product Portfolio
  18. 8.3.5 TetraLogic Recent Developments
  19. 8.4 Repligen
  20. 8.4.1 Repligen Company Information
  21. 8.4.2 Repligen Business Overview
  22. 8.4.3 Repligen Histone Deacetylase (HDAC) Inhibitors Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Repligen Histone Deacetylase (HDAC) Inhibitors Product Portfolio
  24. 8.4.5 Repligen Recent Developments
  25. 8.5 Onxeo
  26. 8.5.1 Onxeo Company Information
  27. 8.5.2 Onxeo Business Overview
  28. 8.5.3 Onxeo Histone Deacetylase (HDAC) Inhibitors Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Onxeo Histone Deacetylase (HDAC) Inhibitors Product Portfolio
  30. 8.5.5 Onxeo Recent Developments
  31. 8.6 Mirati Therapeutics
  32. 8.6.1 Mirati Therapeutics Company Information
  33. 8.6.2 Mirati Therapeutics Business Overview
  34. 8.6.3 Mirati Therapeutics Histone Deacetylase (HDAC) Inhibitors Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Mirati Therapeutics Histone Deacetylase (HDAC) Inhibitors Product Portfolio
  36. 8.6.5 Mirati Therapeutics Recent Developments
  37. 8.7 MEI Pharma
  38. 8.7.1 MEI Pharma Company Information
  39. 8.7.2 MEI Pharma Business Overview
  40. 8.7.3 MEI Pharma Histone Deacetylase (HDAC) Inhibitors Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 MEI Pharma Histone Deacetylase (HDAC) Inhibitors Product Portfolio
  42. 8.7.5 MEI Pharma Recent Developments
  43. 8.8 Curis
  44. 8.8.1 Curis Company Information
  45. 8.8.2 Curis Business Overview
  46. 8.8.3 Curis Histone Deacetylase (HDAC) Inhibitors Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Curis Histone Deacetylase (HDAC) Inhibitors Product Portfolio
  48. 8.8.5 Curis Recent Developments
  49. 8.9 CrystalGenomics
  50. 8.9.1 CrystalGenomics Company Information
  51. 8.9.2 CrystalGenomics Business Overview
  52. 8.9.3 CrystalGenomics Histone Deacetylase (HDAC) Inhibitors Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 CrystalGenomics Histone Deacetylase (HDAC) Inhibitors Product Portfolio
  54. 8.9.5 CrystalGenomics Recent Developments
  55. 8.10 Chroma Therapeutics
  56. 8.10.1 Chroma Therapeutics Company Information
  57. 8.10.2 Chroma Therapeutics Business Overview
  58. 8.10.3 Chroma Therapeutics Histone Deacetylase (HDAC) Inhibitors Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Chroma Therapeutics Histone Deacetylase (HDAC) Inhibitors Product Portfolio
  60. 8.10.5 Chroma Therapeutics Recent Developments
  61. 8.11 Chipscreen Biosciences
  62. 8.11.1 Chipscreen Biosciences Company Information
  63. 8.11.2 Chipscreen Biosciences Business Overview
  64. 8.11.3 Chipscreen Biosciences Histone Deacetylase (HDAC) Inhibitors Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Chipscreen Biosciences Histone Deacetylase (HDAC) Inhibitors Product Portfolio
  66. 8.11.5 Chipscreen Biosciences Recent Developments
  67. 8.12 Celleron Therapeutics
  68. 8.12.1 Celleron Therapeutics Company Information
  69. 8.12.2 Celleron Therapeutics Business Overview
  70. 8.12.3 Celleron Therapeutics Histone Deacetylase (HDAC) Inhibitors Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Celleron Therapeutics Histone Deacetylase (HDAC) Inhibitors Product Portfolio
  72. 8.12.5 Celleron Therapeutics Recent Developments
  73. 8.13 Acetylon Pharmaceuticals
  74. 8.13.1 Acetylon Pharmaceuticals Company Information
  75. 8.13.2 Acetylon Pharmaceuticals Business Overview
  76. 8.13.3 Acetylon Pharmaceuticals Histone Deacetylase (HDAC) Inhibitors Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Acetylon Pharmaceuticals Histone Deacetylase (HDAC) Inhibitors Product Portfolio
  78. 8.13.5 Acetylon Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Histone Deacetylase (HDAC) Inhibitors Value Chain Analysis
  2. 9.1.1 Histone Deacetylase (HDAC) Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Histone Deacetylase (HDAC) Inhibitors Sales Mode & Process
  6. 9.2 Histone Deacetylase (HDAC) Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Histone Deacetylase (HDAC) Inhibitors Distributors
  9. 9.2.3 Histone Deacetylase (HDAC) Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst